nivolumab
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
nivolumab
Jul 23, 2024, 10:09 |
Insight
Ilya Tsimafeyeu: Intrapleural nivolumab in cancer patients with pleural effusion
Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared on Facebook about a recent…
Jul 21, 2024, 08:52 |
Blog
Ece Tolgay: I will be presenting a poster at the ECI2024
Ece Tolgay, Member of American Association of Immunologists, posted on X: …
Jul 20, 2024, 18:07 |
Blog
Tom Powles: More evidence that PD(L)1 re-challenge should be avoided in renal cancer
Tom Powles posted on X/Twitter: "More evidence that PD(L)1 re-challenge should be avoided in renal…
Jul 20, 2024, 10:51 |
Blog
Toni Choueiri: TiNivo2 results are out
Toni Choueiri shared a post on X: ''TiNivo2 results are out - adding PD1 inhibitor…
Jul 9, 2024, 07:25 |
Insight
Piotr Wysocki: Checkpoint inhibitor and TKI combinations in GU malignancies
Piotr Wysocki recently posted on LinkedIn: "A phase I study (Apolo AB et al. J Clin…
Jul 5, 2024, 15:03 |
Drugs
Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours
Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at…
Jul 5, 2024, 13:47 |
Insight
Andrea Apolo: Very proud of this Clinical Trial of Cabozantinib/Nivolumab published at JCO
Shilpa Gupta shared a post by Andrea Apolo, adding: "Huge congrats Andrea Apolo, leading this…
Jul 5, 2024, 02:30 |
Drugs
Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma - ESMO
ESMO shared on LinkedIn: "Benefits reported for the combination of ipilimumab and nivolumab further expand…
Jul 3, 2024, 00:52 |
Blog
Hedyeh Ebrahimi: Intrigued by the difference in response between CBM588 and ctrl arms
Hedyeh Ebrahimi, Postdoctoral fellow at Genitourinary Cancer Research Team of City of Hope shared a…
Jul 1, 2024, 23:51 |
Insight
Piotr Wysocki: Neoadjuvant therapy for renal-cell cancer patients is still in its infancy, unlike in melanoma
Piotr Wysocki recently posted on LinkedIn: "The PROSPER ECOG-ACRIN EA8143 study (published online in Lancet…
Jun 30, 2024, 14:51 |
Insight
Sergio Cifuentes: Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about…
Jun 29, 2024, 14:04 |
Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 29, 2024, 13:50 |
Drugs
Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer
Syed A. Ahmad, Chief of Surgical Oncology at The University of Cincinnati, made the following…
Jun 29, 2024, 12:06 |
Drugs
Injectable form of nivolumab vs the intravenous form against kidney cancer - NCI
National Cancer Institute (NCI) shared on X: "In a Clinical Trial, an injectable form of…
Jun 26, 2024, 14:10 |
Blog
Maria Babak: Rapid Progress in Metastatic Urothelial Carcinoma
Maria Babak shared a post by The Babak Lab on LinkedIn: “The FDA's approval of…
Jun 21, 2024, 13:14 |
Blog
Amol Akhade: What is interesting at ESMO GI24? NEST 1 trial
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X: “What…
Jun 12, 2024, 04:11 |
Insight
Nivolumab and Chemotherapy as First-Line Treatment for Metastatic Gastric Cancer: Updated Analysis and the Impact of FGFR2
"Nivolumab in combination with chemotherapy is the standard first-line treatment for metastatic gastric cancer expressing…
Jun 10, 2024, 15:00 |
Blog
Sumanta K. Pal: PIVOT09 comparing pegylated IL2/nivolumab to TKI by Nizar Tannir et al.
Sumanta K. Pal shared a post on X: “Huge congrats to Nizar Tannir, MD Anderson Cancer…
Jun 8, 2024, 10:07 |
Insight
Ari Rosenberg: Our OPTIMA II trial is out in JAMA Oncology
Ari Rosenberg, Medical Oncologist and Assistant Professor at the University of Chicago, shared a post…
Jun 8, 2024, 09:58 |
Insight
Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors
Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .…
Jun 8, 2024, 06:59 |
Blog
Results of the NICHE-2 trial show it to be highly effective in a subset of patients with colon cancer - The Netherlands Cancer Institute
The Netherlands Cancer Institute shared on Linkedin: “More succes for neoadjuvant immunotherapy: results of the…
Jun 7, 2024, 11:00 |
Blog
Krishan Jethwa: ESOPEC practice shifting trial at ASCO24
Krishan Jethwa, Assistant Professor of Radiation Oncology at Mayo Clinic, shared on X: ''ESOPEC. Practice…
Jun 5, 2024, 04:04 |
Drugs
Jon Wigginton: Very exciting phase 3 data regarding stage 3 melanoma
Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “NEJM…
Jun 5, 2024, 01:48 |
Societies
Toni Choueiri: Poster 269 by our super star Eddy Saad at ASCO24
Toni Choueiri shared a post on X: “Poster American Society of Clinical Oncology (ASCO24) 269 by…
Jun 4, 2024, 13:13 |
Insight
Tanja Obradovic: NADINA trial making history at ASCO2024 plenary session
Tanja Obradovic shared on LinkedIn: . "NADINA trial making history today at ASCO2024 plenary session.…
Jun 2, 2024, 23:50 |
Societies
Rob Rawlinson: Plenty of food for thought during the education session on ADCs at ASCO24
Rob Rawlinson, Lead Director Oncology at Lumanity, recently shared on LinkedIn: "ASCO DAY 2 The…
Jun 2, 2024, 23:47 |
Insight
NADINA is one of the 11 clinical studies with the biggest impact on health care in 2024 - Netherlands Cancer Institute
Quoting The Netherlands Cancer Institute on LinkedIn: "The NADINA study, led by researchers from the…
Jun 2, 2024, 09:37 |
Insight
Allison Betof Warner: Relativity-048 presented by Paolo A. Ascierto at ASCO24
Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford…
May 31, 2024, 15:03 |
Insight
CheckMate 648 review by Erman Akkus
Erman Akkus, Medical Oncologist at Ankara University, shared on X: "First line Nivolumab plus ChT…
May 31, 2024, 07:46 |
Blog
Shushan Hovsepyan: Sarcoma Sessions at ASCO2024!
Shushan Hovsepyan shared a post on LinkedIn: “Sarcoma Sessions at ASCO2024! SARC037: Phase II results…
May 28, 2024, 07:49 |
Insight
Tom Powles: Renal cancer highlights at ASCO24 - KIM1 biomarker data stands out
Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and…
May 24, 2024, 13:24 |
Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Nivolumab plus ipilimumab…
May 23, 2024, 13:33 |
Insight
Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing
Tom Powles, Director of Barts Cancer Center, shared a post on X: "Neoadjuvant chemo/nivolumab with…
May 23, 2024, 00:35 |
Drugs
Toni Choueiri: The story of adaptive IO therapy in RCC
Toni Choueiri recently shared a post by Rana McKay, an Associate Professor of Medicine at…
May 18, 2024, 09:06 |
Blog
Jarushka Naidoo: Perioperative Nivolumab in Stage IIA-IIIB NSCLC
Jarushka Naidoo shared on X/Twitter: ''Ph III CM77T trial at NEJM: Perioperative Nivolumab in Stage…
May 18, 2024, 08:33 |
Blog
Rami Manochakian: Results of Checkmate 77T trial of
Rami Manochakian shared a post on X/Twitter: ''Hot Off The Press. Just published at NEJM.…
May 16, 2024, 16:51 |
Insight
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…
May 14, 2024, 10:35 |
Insight
RELATIVITY-060 - summarized by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University shared a post on X: “Adding relatlimab to…
May 12, 2024, 07:27 |
Drugs
Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: “Based on what…
May 9, 2024, 09:54 |
Insight
Sergio Cifuentes Canaval: My takeaways from new analysis of the CheckMate 9ER trial
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared on LinkedIn: "Nivolumab + Cabozantinib: Numbers…
May 6, 2024, 12:58 |
Blog
Iván R. González: The NEOpredict-Lung study represents an importantevolution in the treatment of resectable NSCLC
Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post…
Apr 28, 2024, 12:38 |
Insight
Piotr Wysocki: Combined treatment (TKI+ICI) does not benefit favorable-risk mRCC patients
Piotr Wysocki recently shared on LinkedIn: "For several years, combined therapy based on the administration of…
Apr 28, 2024, 11:04 |
Blog
Ana I. Velázquez Mañana: ASCO24 abstract titles are out! Exciting Plenary Session, specially for LCSM community
Ana I. Velázquez Mañana shared on X/Twitter: “ASCO24 abstract titles are out! Exciting Plenary Session, specially…
Apr 25, 2024, 19:53 |
Blog
Razelle Kurzrock: SWOG has given us the opportunity to do a national immunotherapy trial for rare tumors
Razelle Kurzrock, Chair of Precision Oncology at MCW Cancer Center, shared a post by SWOG…
Apr 25, 2024, 00:51 |
Insight
New Paper Alert! Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma Authors: T. Powles,…
Apr 16, 2024, 17:00 |
Insight
New Paper Alert! A Novel 3-Gene Expression Score Predicts Immunotherapy Response in Advanced Renal Cell Carcinoma
New Paper Alert! A Novel 3-Gene Expression Score Predicts Immunotherapy Response in Advanced Renal Cell…
Apr 12, 2024, 14:08 |
Insight
Erman Akkus: Pancreatic cancer clinical trials in AACR24
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X: "Pancreatic cancer clinical trials…
Apr 2, 2024, 05:37 |
Drugs
Paolo Tarantino: The OXEL trial is out on Nature Communications
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Apr 1, 2024, 15:31 |
Blog
Tom Powles: Easter paper of the month with Matt Galsky
Tom Powles, Director of Barts Cancer Center, shared a post on X: "Easter paper of…
Mar 31, 2024, 08:44 |
Blog
UCLA Health Jonsson Comprehensive Cancer Center's presentation at the annual meeting of the American Association for Cancer Research (AACR)
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will discuss the latest breakthroughs and cutting-edge science…
Mar 11, 2024, 18:00 |
Societies
Florez Lab: A fantastic discussion on Nivolumab and Non-Small Cell Lung Cancer
Florez Lab posted on X/Twitter: "What podcast should you listen to today? In this episode…
Mar 5, 2024, 12:21 |
Blog
Stephen Liu: In 2012, Dr. Julie Brahmer presented the phase I study of immunotherapy in lung cancer
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown Lombardi, recently shared on…
Feb 11, 2024, 12:01 |
Insight
Vinay Mathew Thomas: Our viewpoint article on CheckMate 901 is now out in Med by Cell Press
Petros Grivas, Associate Professor at the University of Washington, shared an X post by Vinay…
Feb 2, 2024, 17:33 |
Drugs
Day 3 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers recently tweeted: "Day 3 of GU24 ASCO Highlights 1. KN564: Adj Pembro w/…
Jan 29, 2024, 17:32 |
Insight
David Braun: Could really change how nivo is delivered in the future
David Braun, Oncologist, physician-scientist at Yale Cancer Center, shared a post on X/Twitter: "Really nice…
Jan 7, 2024, 15:14 |
Drugs
Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:…
Jan 5, 2024, 11:46 |
Blog
Petros Grivas: This is a product of teamwork for many years
Petros Grivas, Associate Professor at University of Washington, shared on X/Twitter: "This is a product of…
Jan 4, 2024, 16:59 |
Insight
Vinay Prasad: When do the checkpoint inhibitors work
Vinay Prasad, Professor in the Department of Epidemiology and Biostatistics at the University of California…
Dec 12, 2023, 18:30 |
Blog
Andres Gomez: Learn about resource optimization in Low- and Middle-Income Countries with Héctor Vaquera
Andres Gomez, Associate Professor at The Autonomous University of Nuevo León, shared a post on…
Dec 4, 2023, 08:33 |
Blog
Roberto Iacovelli: There is HOPE for kidney cancer patients!
Roberto Iacovelli, Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome,…
Nov 26, 2023, 17:27 |
Insight
Marco Donia: Most combinations in oncology have additive but not synergistic efficacy
Marco Donia, Clinical Research Associate Professor at University of Copenhagen, shared on LinkedIn: "Most combinations…
Nov 14, 2023, 03:56 |
Insight
Guru P. Sonpavde: Honored to write this commentary...
Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X/Twitter: "Nivolumab…
Oct 31, 2023, 09:39 |
Insight
Paolo A. Ascierto: The history of melanoma is changing!
Paolo A. Ascierto, Director Department of Melanoma/Skin Cancers, Cancer Immunotherapy and Development Therapeutics at IRCCS,…
Oct 25, 2023, 17:52 |
Insight
Ilya Tsimafeyeu: Patients with metastatic renal cell carcinoma and high fibrinogen levels who received nivolumab had worse overall survival
Ilya Tsimafeyeu, Director at Bureau of Cancer Research Russia, shared on Facebook: "Our study: Patients…
Sep 19, 2023, 02:48 |
Insight
Ryan Moy: Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed.
Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center,…
Sep 7, 2023, 19:34 |
Blog
,
Drugs
,
Insight
Shruti Patel: Tumor Board Tuesday - Mini tweetorial.
Shruti Patel, Oncology Fellow at Stanford Health Care, recently tweeted: "Tumor Board Tuesday - Mini…
Jun 30, 2023, 19:08 |
Drugs
Perioperative Nivolumab and Chemotherapy in stage III Non-Small-Cell Lung Cancer
In a post by Rami Manochakian on Twitter, it says, "Just published NEJM Results of…
All:
67
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube